IL287555A - binding compounds - Google Patents

binding compounds

Info

Publication number
IL287555A
IL287555A IL287555A IL28755521A IL287555A IL 287555 A IL287555 A IL 287555A IL 287555 A IL287555 A IL 287555A IL 28755521 A IL28755521 A IL 28755521A IL 287555 A IL287555 A IL 287555A
Authority
IL
Israel
Prior art keywords
binding molecules
molecules
binding
Prior art date
Application number
IL287555A
Other languages
English (en)
Hebrew (he)
Original Assignee
Crescendo Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1906870.9A external-priority patent/GB201906870D0/en
Priority claimed from GBGB1906872.5A external-priority patent/GB201906872D0/en
Application filed by Crescendo Biologics Ltd filed Critical Crescendo Biologics Ltd
Publication of IL287555A publication Critical patent/IL287555A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IL287555A 2019-05-15 2021-10-25 binding compounds IL287555A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1906870.9A GB201906870D0 (en) 2019-05-15 2019-05-15 Binding molecules
GBGB1906872.5A GB201906872D0 (en) 2019-05-15 2019-05-15 Binding molecules
PCT/GB2020/051199 WO2020229842A1 (en) 2019-05-15 2020-05-15 Binding molecules

Publications (1)

Publication Number Publication Date
IL287555A true IL287555A (en) 2021-12-01

Family

ID=70847430

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287555A IL287555A (en) 2019-05-15 2021-10-25 binding compounds

Country Status (10)

Country Link
US (2) US20220220215A1 (https=)
EP (2) EP3969474A1 (https=)
JP (1) JP2022532370A (https=)
KR (1) KR20220008839A (https=)
CN (1) CN113840835B (https=)
AU (1) AU2020275926A1 (https=)
CA (1) CA3136598A1 (https=)
IL (1) IL287555A (https=)
SG (1) SG11202111671QA (https=)
WO (2) WO2020229844A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7183163B2 (ja) 2017-01-06 2022-12-05 クレシェンド・バイオロジックス・リミテッド プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体
WO2019092452A1 (en) 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules that bind to cd137 and psma
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
EP4274852A4 (en) * 2021-01-11 2025-02-26 Eutilex Co., Ltd. BISPECIFIC EPITOP-BINDING PROTEIN WITH ANTI-4-1BB ANTIBODY AND PD-1 PROTEIN OR FRAGMENTS THEREOF AND USE THEREOF
GB202205589D0 (en) 2022-04-14 2022-06-01 Crescendo Biologics Ltd Mesothelin binders
JP2026506075A (ja) 2023-02-17 2026-02-20 アブリンクス エン．ヴェー． 新生児型ｆｃ受容体に結合するポリペプチド

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
CA2671581A1 (en) * 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
US20130266567A1 (en) * 2010-12-01 2013-10-10 Haren Arulanantham Anti-serum albumin binding single variable domains
CN106046168A (zh) * 2011-06-23 2016-10-26 埃博灵克斯股份有限公司 结合血清白蛋白的蛋白
US20130302250A1 (en) * 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
WO2014111550A1 (en) * 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
JP6641379B2 (ja) 2014-10-22 2020-02-05 クレシェンド・バイオロジックス・リミテッド トランスジェニックマウス
JP7101621B2 (ja) * 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
RU2022101604A (ru) * 2016-12-07 2022-03-29 Аблинкс Нв Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
CN107674122A (zh) * 2016-12-28 2018-02-09 天津天锐生物科技有限公司 一种识别人血清白蛋白的单域抗体
JP7183163B2 (ja) * 2017-01-06 2022-12-05 クレシェンド・バイオロジックス・リミテッド プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体
GB201711068D0 (en) * 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
KR102625929B1 (ko) * 2017-07-19 2024-01-16 브이아이비 브이지더블유 혈청 알부민 결합제
EP3470426A1 (en) * 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
WO2019092452A1 (en) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules that bind to cd137 and psma

Also Published As

Publication number Publication date
EP3969474A1 (en) 2022-03-23
EP3969473A1 (en) 2022-03-23
CA3136598A1 (en) 2021-11-19
CN113840835B (zh) 2024-06-25
WO2020229842A1 (en) 2020-11-19
JP2022532370A (ja) 2022-07-14
WO2020229844A1 (en) 2020-11-19
US20220227850A1 (en) 2022-07-21
SG11202111671QA (en) 2021-11-29
KR20220008839A (ko) 2022-01-21
CN113840835A (zh) 2021-12-24
AU2020275926A1 (en) 2021-11-18
US20220220215A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
IL281901A (en) Multivalent binding compounds based on IgM and IgA-Fc
IL273631A (en) Special hpv molecules bind
IL275510A (en) Specific antigen-binding molecules-ROR1
GB201901306D0 (en) Multi-domain binding molecules
GB201901305D0 (en) Specific binding molecules
GB201811408D0 (en) CD137 Binding Molecules
IL289867A (en) Immunostimulatory multisegmented binding compounds
IL289415A (en) Claudin-6 binding molecules and their use
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
GB201612520D0 (en) Binding molecules
GB201811410D0 (en) OX40 Binding molecules
IL287555A (en) binding compounds
GB201915282D0 (en) Specific binding molecules
GB202006629D0 (en) Specific binding molecules
GB201702091D0 (en) Specific binding molecules
IL288561A (en) gal9-binding molecules with immunosuppressive activity
IL289266B1 (en) New molecules
SG11202109535SA (en) Cd3 binding molecules
IL269752B (en) fgfr3 binding molecules
GB201906118D0 (en) Anti-LAG-3 binding molecules
GB202010329D0 (en) Specific binding molecules
GB201803178D0 (en) Specific binding molecules for htert
GB201904328D0 (en) Specific binding molecules
EP3976199A4 (en) ACTIVATION OF ANTI-GAL9 ANTIBODY BINDING MOLECULES
ZA202200734B (en) Binding members